EMA Authorised: Gilenya (fingolimod hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

Gilenya (fingolimod hydrochloride) has been authorised for use in the European Union for multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Novartis Europharm Limited. Decision date: 11/06/2026